In week 52 responders with moderate-to-severe hidradenitis suppurativa, randomised withdrawal to placebo vs continued secukinumab did not meet the primary endpoint of time to loss of response (risk reduction 13%, P=0.25 every 2 weeks; 30%, P=0.04 every 4 weeks).
RCT
Kimball et al. Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: week 104 results from the SUNSHINE and SUNRISE extension trial